Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 1996 Dec;104(Suppl 6):1239–1246. doi: 10.1289/ehp.961041239

The process of leukemogenesis.

R D Irons 1, W S Stillman 1
PMCID: PMC1469736  PMID: 9118899

Abstract

Leukemias are monoclonal diseases that arise from cells in the hematopoietic stem and progenitor cell compartment. Consistent with emerging models of carcinogenesis, leukemogenesis is an evolutionary process that involves multiple independent genetic and epigenetic events. Over the last half-century a predominant paradigm has emerged to describe leukemia developing secondary to alkylating drug therapy or exposure to benzene in which progressive dysplastic changes, accompanied by a distinct pattern of clonal cytogenetic abnormalities, give rise to acute myelogenous leukemia. Characterization of these clonal chromosomal aberrations, together with observed alterations in other growth-promoting genes, provides a useful framework for studying chemical leukemogenesis and for use in understanding the origins and development of leukemia in general.

Full text

PDF
1239

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Advani S. H., Doval D. C., Gopal R., Nair C. N., Kutty P. M. Therapy-related leukemia. A report of five patients and a review of the literature. Oncology. 1983;40(4):268–272. doi: 10.1159/000225741. [DOI] [PubMed] [Google Scholar]
  2. Allan W. S. Acute myeloid leukaemia after treatment with cytostatic agents. Lancet. 1970 Oct 10;2(7676):775–775. doi: 10.1016/s0140-6736(70)90250-3. [DOI] [PubMed] [Google Scholar]
  3. Anderson R. L., Bagby G. C., Jr, Richert-Boe K., Magenis R. E., Koler R. D. Therapy-related preleukemic syndrome. Cancer. 1981 Apr 1;47(7):1867–1871. doi: 10.1002/1097-0142(19810401)47:7<1867::aid-cncr2820470725>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  4. Bagby G. C., Jr, Wilkinson B., McCall E., Lee M. Abnormalities of the hematopoietic regulatory network. Adv Exp Med Biol. 1988;241:255–264. doi: 10.1007/978-1-4684-5571-7_28. [DOI] [PubMed] [Google Scholar]
  5. Bartolucci A. A., Liu C., Durant J. R., Gams R. A. Acute myelogenous leukemia as a second malignant neoplasm following the successful treatment of advanced Hodgkin's disease. Cancer. 1983 Dec 15;52(12):2209–2213. doi: 10.1002/1097-0142(19831215)52:12<2209::aid-cncr2820521206>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  6. Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982 Jun;51(2):189–199. [PubMed] [Google Scholar]
  7. Bitter M. A., Le Beau M. M., Rowley J. D., Larson R. A., Golomb H. M., Vardiman J. W. Associations between morphology, karyotype, and clinical features in myeloid leukemias. Hum Pathol. 1987 Mar;18(3):211–225. doi: 10.1016/s0046-8177(87)80002-3. [DOI] [PubMed] [Google Scholar]
  8. Bloomfield C. D., Goldman A., Hassfeld D., de la Chapelle A. Fourth International Workshop on Chromosomes in Leukemia 1982: Clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. Cancer Genet Cytogenet. 1984 Mar;11(3):332–350. doi: 10.1016/s0165-4608(84)80022-9. [DOI] [PubMed] [Google Scholar]
  9. Bodine D. M., Orlic D., Birkett N. C., Seidel N. E., Zsebo K. M. Stem cell factor increases colony-forming unit-spleen number in vitro in synergy with interleukin-6, and in vivo in Sl/Sld mice as a single factor. Blood. 1992 Feb 15;79(4):913–919. [PubMed] [Google Scholar]
  10. Boivin J. F., Hutchison G. B. Leukemia and other cancers after radiotherapy and chemotherapy for Hodgkin's disease. J Natl Cancer Inst. 1981 Oct;67(4):751–760. [PubMed] [Google Scholar]
  11. Casciato D. A., Scott J. L. Acute leukemia following prolonged cytotoxic agent therapy. Medicine (Baltimore) 1979 Jan;58(1):32–47. doi: 10.1097/00005792-197901000-00002. [DOI] [PubMed] [Google Scholar]
  12. Chang J. M., Metcalf D., Lang R. A., Gonda T. J., Johnson G. R. Nonneoplastic hematopoietic myeloproliferative syndrome induced by dysregulated multi-CSF (IL-3) expression. Blood. 1989 May 1;73(6):1487–1497. [PubMed] [Google Scholar]
  13. Chen C. Y., Oliner J. D., Zhan Q., Fornace A. J., Jr, Vogelstein B., Kastan M. B. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2684–2688. doi: 10.1073/pnas.91.7.2684. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Coleman C. N., Williams C. J., Flint A., Glatstein E. J., Rosenberg S. A., Kaplan H. S. Hematologic neoplasia in patients treated for Hodgkin's disease. N Engl J Med. 1977 Dec 8;297(23):1249–1252. doi: 10.1056/NEJM197712082972303. [DOI] [PubMed] [Google Scholar]
  15. Coltman C. A., Jr, Dahlberg S. Treatment-related leukemia. N Engl J Med. 1990 Jan 4;322(1):52–53. doi: 10.1056/NEJM199001043220109. [DOI] [PubMed] [Google Scholar]
  16. Coutinho L. H., Geary C. G., Chang J., Harrison C., Testa N. G. Functional studies of bone marrow haemopoietic and stromal cells in the myelodysplastic syndrome (MDS). Br J Haematol. 1990 May;75(1):16–25. doi: 10.1111/j.1365-2141.1990.tb02611.x. [DOI] [PubMed] [Google Scholar]
  17. Crane M. M., Keating M. J., Trujillo J. M., Labarthe D. R., Frankowski R. F. Environmental exposures in cytogenetically defined subsets of acute nonlymphocytic leukemia. JAMA. 1989 Aug 4;262(5):634–639. [PubMed] [Google Scholar]
  18. Cronkite E. P., Drew R. T., Inoue T., Hirabayashi Y., Bullis J. E. Hematotoxicity and carcinogenicity of inhaled benzene. Environ Health Perspect. 1989 Jul;82:97–108. doi: 10.1289/ehp.898297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Cuneo A., Fagioli F., Pazzi I., Tallarico A., Previati R., Piva N., Carli M. G., Balboni M., Castoldi G. Morphologic, immunologic and cytogenetic studies in acute myeloid leukemia following occupational exposure to pesticides and organic solvents. Leuk Res. 1992 Aug;16(8):789–796. doi: 10.1016/0145-2126(92)90158-4. [DOI] [PubMed] [Google Scholar]
  20. Decouflé P., Blattner W. A., Blair A. Mortality among chemical workers exposed to benzene and other agents. Environ Res. 1983 Feb;30(1):16–25. doi: 10.1016/0013-9351(83)90161-5. [DOI] [PubMed] [Google Scholar]
  21. Dempster A. M., Snyder C. A. Short term benzene exposure provides a growth advantage for granulopoietic progenitor cells over erythroid progenitor cells. Arch Toxicol. 1990;64(7):539–544. doi: 10.1007/BF01971832. [DOI] [PubMed] [Google Scholar]
  22. Devereux S. Therapy associated leukaemia. Blood Rev. 1991 Sep;5(3):138–145. doi: 10.1016/0268-960x(91)90030-g. [DOI] [PubMed] [Google Scholar]
  23. FOULDS L. The experimental study of tumor progression: a review. Cancer Res. 1954 Jun;14(5):327–339. [PubMed] [Google Scholar]
  24. Fagioli F., Cuneo A., Piva N., Carli M. G., Previati R., Balboni M., Tomasi P., Cariani D., Scapoli G., Castoldi G. Distinct cytogenetic and clinicopathologic features in acute myeloid leukemia after occupational exposure to pesticides and organic solvents. Cancer. 1992 Jul 1;70(1):77–85. doi: 10.1002/1097-0142(19920701)70:1<77::aid-cncr2820700113>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  25. Farr C. J., Saiki R. K., Erlich H. A., McCormick F., Marshall C. J. Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. Proc Natl Acad Sci U S A. 1988 Mar;85(5):1629–1633. doi: 10.1073/pnas.85.5.1629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Farris G. M., Everitt J. I., Irons R. D., Popp J. A. Carcinogenicity of inhaled benzene in CBA mice. Fundam Appl Toxicol. 1993 May;20(4):503–507. doi: 10.1006/faat.1993.1061. [DOI] [PubMed] [Google Scholar]
  27. Forni A., Vigliani E. C. Chemical leukemogenesis in man. Ser Haematol. 1974;7(2):211–223. [PubMed] [Google Scholar]
  28. Foucar K., McKenna R. W., Bloomfield C. D., Bowers T. K., Brunning R. D. Therapy-related leukemia: a panmyelosis. Cancer. 1979 Apr;43(4):1285–1296. doi: 10.1002/1097-0142(197904)43:4<1285::aid-cncr2820430416>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  29. Furukawa Y., DeCaprio J. A., Belvin M., Griffin J. D. Heterogeneous expression of the product of the retinoblastoma susceptibility gene in primary human leukemia cells. Oncogene. 1991 Aug;6(8):1343–1346. [PubMed] [Google Scholar]
  30. Gibson F. M., Bagnara M., Ioannidou E., Gordon-Smith E. C. Interaction of granulocyte-macrophage colony-stimulating factor and interleukin 3 in human long-term bone marrow culture. Exp Hematol. 1992 Feb;20(2):235–240. [PubMed] [Google Scholar]
  31. Golomb H. M., Alimena G., Rowley J. D., Vardiman J. W., Testa J. R., Sovik C. Correlation of occupation and karyotype in adults with acute nonlymphocytic leukemia. Blood. 1982 Aug;60(2):404–411. [PubMed] [Google Scholar]
  32. Greenberg B. R., Wilson F. Z., Woo L. Granulopoietic effects of human bone marrow fibroblastic cells and abnormalities in the "granulopoietic microenvironment". Blood. 1981 Sep;58(3):557–564. [PubMed] [Google Scholar]
  33. Greene M. H., Harris E. L., Gershenson D. M., Malkasian G. D., Jr, Melton L. J., 3rd, Dembo A. J., Bennett J. M., Moloney W. C., Boice J. D., Jr Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med. 1986 Sep;105(3):360–367. doi: 10.7326/0003-4819-105-3-360. [DOI] [PubMed] [Google Scholar]
  34. Grünwald H. W., Rosner F. Acute leukemia and immunosupressive drug use: a review of patients undergoing immunosuppressive therapy for non-neoplastic diseases. Arch Intern Med. 1979 Apr;139(4):461–466. [PubMed] [Google Scholar]
  35. Grünwald H. W., Rosner F. Acute myeloid leukemia following treatment of Hodgkin's disease: a review. Cancer. 1982 Aug 15;50(4):676–683. doi: 10.1002/1097-0142(19820815)50:4<676::aid-cncr2820500410>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  36. Hirai H., Okada M., Mizoguchi H., Mano H., Kobayashi Y., Nishida J., Takaku F. Relationship between an activated N-ras oncogene and chromosomal abnormality during leukemic progression from myelodysplastic syndrome. Blood. 1988 Jan;71(1):256–258. [PubMed] [Google Scholar]
  37. Holden J. T., Geller R. B., Farhi D. C., Holland H. K., Stempora L. L., Phillips C. N., Bray R. A. Characterization of Thy-1 (CDw90) expression in CD34+ acute leukemia. Blood. 1995 Jul 1;86(1):60–65. [PubMed] [Google Scholar]
  38. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  39. Hoppe R. T. Secondary leukemia and myelodysplastic syndrome after treatment for Hodgkin's disease. Leukemia. 1992 Nov;6 (Suppl 4):155–157. [PubMed] [Google Scholar]
  40. Ikebuchi K., Clark S. C., Ihle J. N., Souza L. M., Ogawa M. Granulocyte colony-stimulating factor enhances interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci U S A. 1988 May;85(10):3445–3449. doi: 10.1073/pnas.85.10.3445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Irons R. D., Stillman W. S. Cell proliferation and differentiation in chemical leukemogenesis. Stem Cells. 1993 May;11(3):235–242. doi: 10.1002/stem.5530110311. [DOI] [PubMed] [Google Scholar]
  42. Irons R. D., Stillman W. S., Colagiovanni D. B., Henry V. A. Synergistic action of the benzene metabolite hydroquinone on myelopoietic stimulating activity of granulocyte/macrophage colony-stimulating factor in vitro. Proc Natl Acad Sci U S A. 1992 May 1;89(9):3691–3695. doi: 10.1073/pnas.89.9.3691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Johansson B., Mertens F., Heim S., Kristoffersson U., Mitelman F. Cytogenetics of secondary myelodysplasia (sMDS) and acute nonlymphocytic leukemia (sANLL). Eur J Haematol. 1991 Jul;47(1):17–27. doi: 10.1111/j.1600-0609.1991.tb00556.x. [DOI] [PubMed] [Google Scholar]
  44. Kaldor J. M., Day N. E., Pettersson F., Clarke E. A., Pedersen D., Mehnert W., Bell J., Høst H., Prior P., Karjalainen S. Leukemia following chemotherapy for ovarian cancer. N Engl J Med. 1990 Jan 4;322(1):1–6. doi: 10.1056/NEJM199001043220101. [DOI] [PubMed] [Google Scholar]
  45. Kantarjian H. M., Keating M. J., Walters R. S., Smith T. L., Cork A., McCredie K. B., Freireich E. J. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol. 1986 Dec;4(12):1748–1757. doi: 10.1200/JCO.1986.4.12.1748. [DOI] [PubMed] [Google Scholar]
  46. Kastan M. B., Strauss L. C., Civin C. I. The role of hematopoietic growth factors and oncogenes in leukemogenesis. Am J Pediatr Hematol Oncol. 1989 Fall;11(3):249–267. [PubMed] [Google Scholar]
  47. Knudson A. G., Jr Hereditary cancers disclose a class of cancer genes. Cancer. 1989 May 15;63(10):1888–1891. doi: 10.1002/1097-0142(19890515)63:10<1888::aid-cncr2820631004>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  48. Koike K., Ogawa M., Ihle J. N., Miyake T., Shimizu T., Miyajima A., Yokota T., Arai K. Recombinant murine granulocyte-macrophage (GM) colony-stimulating factor supports formation of GM and multipotential blast cell colonies in culture: comparison with the effects of interleukin-3. J Cell Physiol. 1987 Jun;131(3):458–464. doi: 10.1002/jcp.1041310319. [DOI] [PubMed] [Google Scholar]
  49. Kornblau S. M., Xu H. J., del Giglio A., Hu S. X., Zhang W., Calvert L., Beran M., Estey E., Andreeff M., Trujillo J. Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemia. Cancer Res. 1992 Sep 1;52(17):4587–4590. [PubMed] [Google Scholar]
  50. Kroef M. J., Fibbe W. E., Mout R., Jansen R. P., Haak H. L., Wessels J. W., Van Kamp H., Willemze R., Landegent J. E. Myeloid but not lymphoid cells carry the 5q deletion: polymerase chain reaction analysis of loss of heterozygosity using mini-repeat sequences on highly purified cell fractions. Blood. 1993 Apr 1;81(7):1849–1854. [PubMed] [Google Scholar]
  51. Kubo K., Naoe T., Kiyoi H., Fukutani H., Kato Y., Oguri T., Yamamori S., Akatsuka Y., Kodera Y., Ohno R. Clonal analysis of multiple point mutations in the N-ras gene in patients with acute myeloid leukemia. Jpn J Cancer Res. 1993 Apr;84(4):379–387. doi: 10.1111/j.1349-7006.1993.tb00147.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Kyle R. A. Second malignancies associated with chemotherapeutic agents. Semin Oncol. 1982 Mar;9(1):131–142. [PubMed] [Google Scholar]
  53. Land H., Parada L. F., Weinberg R. A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature. 1983 Aug 18;304(5927):596–602. doi: 10.1038/304596a0. [DOI] [PubMed] [Google Scholar]
  54. Lang R. A., Metcalf D., Gough N. M., Dunn A. R., Gonda T. J. Expression of a hemopoietic growth factor cDNA in a factor-dependent cell line results in autonomous growth and tumorigenicity. Cell. 1985 Dec;43(2 Pt 1):531–542. doi: 10.1016/0092-8674(85)90182-5. [DOI] [PubMed] [Google Scholar]
  55. Layton D. M., Mufti G. J. Myelodysplastic syndromes: their history, evolution and relation to acute myeloid leukaemia. Blut. 1986 Dec;53(6):423–436. doi: 10.1007/BF00320305. [DOI] [PubMed] [Google Scholar]
  56. Le Beau M. M., Albain K. S., Larson R. A., Vardiman J. W., Davis E. M., Blough R. R., Golomb H. M., Rowley J. D. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol. 1986 Mar;4(3):325–345. doi: 10.1200/JCO.1986.4.3.325. [DOI] [PubMed] [Google Scholar]
  57. Le Beau M. M., Rowley J. D. Chromosomal abnormalities in leukemia and lymphoma: clinical and biological significance. Adv Hum Genet. 1986;15:1–54. doi: 10.1007/978-1-4615-8356-1_1. [DOI] [PubMed] [Google Scholar]
  58. Leary A. G., Yang Y. C., Clark S. C., Gasson J. C., Golde D. W., Ogawa M. Recombinant gibbon interleukin 3 supports formation of human multilineage colonies and blast cell colonies in culture: comparison with recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1987 Nov;70(5):1343–1348. [PubMed] [Google Scholar]
  59. Leary A. G., Zeng H. Q., Clark S. C., Ogawa M. Growth factor requirements for survival in G0 and entry into the cell cycle of primitive human hemopoietic progenitors. Proc Natl Acad Sci U S A. 1992 May 1;89(9):4013–4017. doi: 10.1073/pnas.89.9.4013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Levine E. G., Bloomfield C. D. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol. 1992 Feb;19(1):47–84. [PubMed] [Google Scholar]
  61. Lishner M., Slingerland J., Barr J., Panzarella T., Degendorfer P., Sutcliffe S. Second malignant neoplasms in patients with non Hodgkin's lymphoma. Hematol Oncol. 1991 May-Jun;9(3):169–179. doi: 10.1002/hon.2900090308. [DOI] [PubMed] [Google Scholar]
  62. Lithotripsy. Health and Public Policy Committee, American College of Physicians. Ann Intern Med. 1985 Oct;103(4):626–629. [PubMed] [Google Scholar]
  63. Liu E. T. The role of ras gene mutations in myeloproliferative disorders. Clin Lab Med. 1990 Dec;10(4):797–807. [PubMed] [Google Scholar]
  64. Luna-Fineman S., Shannon K. M., Lange B. J. Childhood monosomy 7: epidemiology, biology, and mechanistic implications. Blood. 1995 Apr 15;85(8):1985–1999. [PubMed] [Google Scholar]
  65. Michels S. D., McKenna R. W., Arthur D. C., Brunning R. D. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood. 1985 Jun;65(6):1364–1372. [PubMed] [Google Scholar]
  66. Miller J. S., Arthur D. C., Litz C. E., Neglia J. P., Miller W. J., Weisdorf D. J. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood. 1994 Jun 15;83(12):3780–3786. [PubMed] [Google Scholar]
  67. Mitelman F., Brandt L., Nilsson P. G. Relation among occupational exposure to potential mutagenic/carcinogenic agents, clinical findings, and bone marrow chromosomes in acute nonlymphocytic leukemia. Blood. 1978 Dec;52(6):1229–1237. [PubMed] [Google Scholar]
  68. Mitelman F., Nilsson P. G., Brandt L., Alimena G., Gastaldi R., Dallapiccola B. Chromosome pattern, occupation, and clinical features in patients with acute nonlymphocytic leukemia. Cancer Genet Cytogenet. 1981 Nov;4(3):197–214. doi: 10.1016/0165-4608(81)90014-5. [DOI] [PubMed] [Google Scholar]
  69. Murphree A. L., Benedict W. F. Retinoblastoma: clues to human oncogenesis. Science. 1984 Mar 9;223(4640):1028–1033. doi: 10.1126/science.6320372. [DOI] [PubMed] [Google Scholar]
  70. Narod S. A., Dubé I. D. Occupational history and involvement of chromosomes 5 and 7 in acute nonlymphocytic leukemia. Cancer Genet Cytogenet. 1989 Apr;38(2):261–269. doi: 10.1016/0165-4608(89)90668-7. [DOI] [PubMed] [Google Scholar]
  71. Nimer S. D., Golde D. W. The 5q- abnormality. Blood. 1987 Dec;70(6):1705–1712. [PubMed] [Google Scholar]
  72. Ogawa M., Matsuzaki Y., Nishikawa S., Hayashi S., Kunisada T., Sudo T., Kina T., Nakauchi H., Nishikawa S. Expression and function of c-kit in hemopoietic progenitor cells. J Exp Med. 1991 Jul 1;174(1):63–71. doi: 10.1084/jem.174.1.63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Pech N., Hermine O., Goldwasser E. Further study of internal autocrine regulation of multipotent hematopoietic cells. Blood. 1993 Sep 1;82(5):1502–1506. [PubMed] [Google Scholar]
  74. Pedersen-Bjergaard J., Larsen S. O. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N Engl J Med. 1982 Oct 14;307(16):965–971. doi: 10.1056/NEJM198210143071601. [DOI] [PubMed] [Google Scholar]
  75. Pedersen-Bjergaard J., Nissen N. I., Sørensen H. M., Hou-Jensen K., Larsen M. S., Ernst P., Ersbøl J., Knudtzon S., Rose C. Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with Treosulfan (= dihydroxybusulfan). Cancer. 1980 Jan 1;45(1):19–29. doi: 10.1002/1097-0142(19800101)45:1<19::aid-cncr2820450106>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  76. Pedersen-Bjergaard J., Philip P., Larsen S. O., Jensen G., Byrsting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood. 1990 Sep 15;76(6):1083–1091. [PubMed] [Google Scholar]
  77. Pedersen-Bjergaard J., Philip P., Mortensen B. T., Ersbøll J., Jensen G., Panduro J., Thomsen M. Acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. Clinical and cytogenetic characteristics and results of in vitro culture of bone marrow and HLA typing. Blood. 1981 Apr;57(4):712–723. [PubMed] [Google Scholar]
  78. Pedersen-Bjergaard J., Philip P., Pedersen N. T., Hou-Jensen K., Svejgaard A., Jensen G., Nissen N. I. Acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. II. Bone marrow cytology, cytogenetics, results of HLA typing, response to antileukemic chemotherapy, and survival in a total series of 55 patients. Cancer. 1984 Aug 1;54(3):452–462. doi: 10.1002/1097-0142(19840801)54:3<452::aid-cncr2820540313>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  79. Pedersen-Bjergaard J. Radiotherapy- and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review. Leuk Res. 1992;16(1):61–65. doi: 10.1016/0145-2126(92)90102-d. [DOI] [PubMed] [Google Scholar]
  80. Raza A., Gezer S., Mundle S., Gao X. Z., Alvi S., Borok R., Rifkin S., Iftikhar A., Shetty V., Parcharidou A. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 1995 Jul 1;86(1):268–276. [PubMed] [Google Scholar]
  81. Raza A., Mundle S., Iftikhar A., Gregory S., Marcus B., Khan Z., Alvi S., Shetty V., Dameron S., Wright V. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Hematol. 1995 Mar;48(3):143–154. doi: 10.1002/ajh.2830480302. [DOI] [PubMed] [Google Scholar]
  82. Ridge S. A., Worwood M., Oscier D., Jacobs A., Padua R. A. FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc Natl Acad Sci U S A. 1990 Feb;87(4):1377–1380. doi: 10.1073/pnas.87.4.1377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Rosner F., Grünwald H. Hodgkin's disease and acute leukemia. Report of eight cases and review of the literature. Am J Med. 1975 Mar;58(3):339–353. doi: 10.1016/0002-9343(75)90600-2. [DOI] [PubMed] [Google Scholar]
  84. Rosner F., Grünwald H. Multiple myeloma terminating in acute leukemia. Report of 12 cases and review of the literature. Am J Med. 1974 Dec;57(6):927–939. doi: 10.1016/0002-9343(74)90171-5. [DOI] [PubMed] [Google Scholar]
  85. Rothman N., Haas R., Hayes R. B., Li G. L., Wiemels J., Campleman S., Quintana P. J., Xi L. J., Dosemeci M., Titenko-Holland N. Benzene induces gene-duplicating but not gene-inactivating mutations at the glycophorin A locus in exposed humans. Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):4069–4073. doi: 10.1073/pnas.92.9.4069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Rowley J. D., Golomb H. M., Vardiman J. W. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood. 1981 Oct;58(4):759–767. [PubMed] [Google Scholar]
  87. Rowley J. D., Le Beau M. M. Cytogenetic and molecular analysis of therapy-related leukemia. Ann N Y Acad Sci. 1989;567:130–140. doi: 10.1111/j.1749-6632.1989.tb16465.x. [DOI] [PubMed] [Google Scholar]
  88. Sachs L., Lotem J. Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood. 1993 Jul 1;82(1):15–21. [PubMed] [Google Scholar]
  89. Sawada K., Sato N., Notoya A., Tarumi T., Hirayama S., Takano H., Koizumi K., Yasukouchi T., Yamaguchi M., Koike T. Proliferation and differentiation of myelodysplastic CD34+ cells: phenotypic subpopulations of marrow CD34+ cells. Blood. 1995 Jan 1;85(1):194–202. [PubMed] [Google Scholar]
  90. Smit C. G., Meyler L. Acute myeloid leukaemia after treatment with cytostatic agents. Lancet. 1970 Sep 26;2(7674):671–672. doi: 10.1016/s0140-6736(70)91448-0. [DOI] [PubMed] [Google Scholar]
  91. Soloff R. S., Dempsey D., Jennings S. R., Wolcott R. M., Chervenak R. Characterization of the progeny of pre-T cells maintained in vitro by IL-3: appearance in the periphery and V beta utilization in vivo. Cell Immunol. 1991 Jun;135(1):132–142. doi: 10.1016/0008-8749(91)90260-i. [DOI] [PubMed] [Google Scholar]
  92. Soussi T., Jonveaux P. p53 gene alterations in human hematological malignancies: a review. Nouv Rev Fr Hematol. 1991;33(6):477–480. [PubMed] [Google Scholar]
  93. Stocking C., Löliger C., Kawai M., Suciu S., Gough N., Ostertag W. Identification of genes involved in growth autonomy of hematopoietic cells by analysis of factor-independent mutants. Cell. 1988 Jun 17;53(6):869–879. doi: 10.1016/s0092-8674(88)90329-7. [DOI] [PubMed] [Google Scholar]
  94. Taylor J. A., Sandler D. P., Bloomfield C. D., Shore D. L., Ball E. D., Neubauer A., McIntyre O. R., Liu E. ras oncogene activation and occupational exposures in acute myeloid leukemia. J Natl Cancer Inst. 1992 Nov 4;84(21):1626–1632. doi: 10.1093/jnci/84.21.1626. [DOI] [PubMed] [Google Scholar]
  95. Toksoz D., Farr C. J., Marshall C. J. ras gene activation in a minor proportion of the blast population in acute myeloid leukemia. Oncogene. 1987;1(4):409–413. [PubMed] [Google Scholar]
  96. Trump D. L., Cowall D. E. Acute myelogenous leukemia as a late complication of the multimodality therapy for Hodgkin's disease. Johns Hopkins Med J. 1977 Nov;141(5):249–251. [PubMed] [Google Scholar]
  97. Tsunoda J., Okada S., Suda J., Nagayoshi K., Nakauchi H., Hatake K., Miura Y., Suda T. In vivo stem cell function of interleukin-3-induced blast cells. Blood. 1991 Jul 15;78(2):318–322. [PubMed] [Google Scholar]
  98. Tucker M. A., Coleman C. N., Cox R. S., Varghese A., Rosenberg S. A. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med. 1988 Jan 14;318(2):76–81. doi: 10.1056/NEJM198801143180203. [DOI] [PubMed] [Google Scholar]
  99. Van den Berghe H., Louwagie A., Broeckaert-Van Orshoven A., David G., Verwilghen R. Chromosome analysis in two unusual malignant blood disorders presumably induced by benzene. Blood. 1979 Apr;53(4):558–566. [PubMed] [Google Scholar]
  100. Van den Berghe H., Vermaelen K., Mecucci C., Barbieri D., Tricot G. The 5q-anomaly. Cancer Genet Cytogenet. 1985 Jul;17(3):189–255. doi: 10.1016/0165-4608(85)90016-0. [DOI] [PubMed] [Google Scholar]
  101. Vigliani E. C., Forni A. Benzene and leukemia. Environ Res. 1976 Feb;11(1):122–127. doi: 10.1016/0013-9351(76)90115-8. [DOI] [PubMed] [Google Scholar]
  102. Vogelstein B., Fearon E. R., Hamilton S. R., Kern S. E., Preisinger A. C., Leppert M., Nakamura Y., White R., Smits A. M., Bos J. L. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988 Sep 1;319(9):525–532. doi: 10.1056/NEJM198809013190901. [DOI] [PubMed] [Google Scholar]
  103. Weinberg R. A. The retinoblastoma protein and cell cycle control. Cell. 1995 May 5;81(3):323–330. doi: 10.1016/0092-8674(95)90385-2. [DOI] [PubMed] [Google Scholar]
  104. Willman C. L., Whittaker M. H. The molecular biology of acute myeloid leukemia. Proto-oncogene expression and function in normal and neoplastic myeloid cells. Clin Lab Med. 1990 Dec;10(4):769–796. [PubMed] [Google Scholar]
  105. Wood P. M., Jordan R. K., Givan A. L., Brooks C. G. IL-3 and IL-4 affect thymocyte differentiation in organ culture. Immunology. 1990 Sep;71(1):83–89. [PMC free article] [PubMed] [Google Scholar]
  106. Young D. C., Wagner K., Griffin J. D. Constitutive expression of the granulocyte-macrophage colony-stimulating factor gene in acute myeloblastic leukemia. J Clin Invest. 1987 Jan;79(1):100–106. doi: 10.1172/JCI112769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  107. Young K. M. Myeloproliferative disorders. Vet Clin North Am Small Anim Pract. 1985 Jul;15(4):769–781. doi: 10.1016/s0195-5616(85)50035-2. [DOI] [PubMed] [Google Scholar]
  108. Zwierzina H., Schöllenberger S., Herold M., Schmalzl F., Besemer J. Endogenous serum levels and surface receptor expression of GM-CSF and IL-3 in patients with myelodysplastic syndromes. Leuk Res. 1992 Dec;16(12):1181–1186. doi: 10.1016/0145-2126(92)90116-o. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES